华润医药(03320.HK)拟收购博雅生物(300294.SZ)控股权
格隆汇 9 月 28日丨华润医药(03320.HK)发布公告,公司全资附属公司华润医药控股已与深圳市高特佳投资集团有限公司订立有关建议收购事项的意向书。华润医药控股拟收购博雅生物制药集团股份有限公司的控股权,而建议收购事项的条款须待华润医药控股与卖方进行进一步磋商后,方可作实。
目标公司博雅生物制药集团股份有限公司(300294.SZ)在深圳证券交易所上市,从事生产医药产品业务。目标公司主要从事开发、生产及销售血液制品、糖尿病药物、抗感染化学药品及生化药品等其他产品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.